+

WO2000055624A3 - Elisa kit for the determination of metabolic phenotypes - Google Patents

Elisa kit for the determination of metabolic phenotypes Download PDF

Info

Publication number
WO2000055624A3
WO2000055624A3 PCT/CA2000/000246 CA0000246W WO0055624A3 WO 2000055624 A3 WO2000055624 A3 WO 2000055624A3 CA 0000246 W CA0000246 W CA 0000246W WO 0055624 A3 WO0055624 A3 WO 0055624A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyp
elisa kit
determination
metabolic phenotypes
elisa
Prior art date
Application number
PCT/CA2000/000246
Other languages
French (fr)
Other versions
WO2000055624A2 (en
Inventor
Brian Leyland-Jones
Pierre Wong
Original Assignee
Leyland Jones Brian
Pierre Wong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leyland Jones Brian, Pierre Wong filed Critical Leyland Jones Brian
Priority to JP2000605205A priority Critical patent/JP2002539450A/en
Priority to EP00908867A priority patent/EP1163518A2/en
Priority to AU31388/00A priority patent/AU3138800A/en
Priority to CA002366085A priority patent/CA2366085A1/en
Publication of WO2000055624A2 publication Critical patent/WO2000055624A2/en
Publication of WO2000055624A3 publication Critical patent/WO2000055624A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to an enzyme linked immunosorbent assay (ELISA) kit for the rapid determination of metabolic phenotypes including but not limited to CYP 1A2, N-acetyltamferase-1 (NAT-1), CYP 2P6, CYP 2E1 and CYP 3A4, which can be used on a routine basis in a clinical laboratory. The ELISA kit allows physicians to a) individualize therapy of drugs such as theophylline, tamoxifen, and clozapine and b) to predict susceptibility to carcinogen induced diseases such as colon rectal cancers. To reduce the number of patients undergoing clinical testing by selecting for patients with the appropriate phenotype most likely to respond.
PCT/CA2000/000246 1999-03-15 2000-03-09 Elisa kit for the determination of metabolic phenotypes WO2000055624A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000605205A JP2002539450A (en) 1999-03-15 2000-03-09 ELISA kit for metabolic phenotyping
EP00908867A EP1163518A2 (en) 1999-03-15 2000-03-09 Elisa kit for the determination of metabolic phenotypes
AU31388/00A AU3138800A (en) 1999-03-15 2000-03-09 Elisa kit for the determination of metabolic phenotypes
CA002366085A CA2366085A1 (en) 1999-03-15 2000-03-09 Elisa kit for the determination of metabolic phenotypes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12448899P 1999-03-15 1999-03-15
US60/124,488 1999-03-15

Publications (2)

Publication Number Publication Date
WO2000055624A2 WO2000055624A2 (en) 2000-09-21
WO2000055624A3 true WO2000055624A3 (en) 2001-02-01

Family

ID=22415174

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000246 WO2000055624A2 (en) 1999-03-15 2000-03-09 Elisa kit for the determination of metabolic phenotypes

Country Status (5)

Country Link
EP (1) EP1163518A2 (en)
JP (1) JP2002539450A (en)
AU (1) AU3138800A (en)
CA (1) CA2366085A1 (en)
WO (1) WO2000055624A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091975A1 (en) * 2001-02-09 2003-05-15 Brian Leyland-Jones Multiple determinants for metabolic phenotypes
US20030138377A1 (en) * 2001-02-28 2003-07-24 Brian Leyland-Jones Use of metabolic phenotyping in individualized treatment with amonafide
US20030072710A1 (en) * 2001-03-14 2003-04-17 Mcgill University Individualization of therapy with antidepressants
AU2002244568A1 (en) * 2001-03-14 2002-09-24 Mcgill University Individualization of therapy with antipsychotics
US20030175210A1 (en) * 2001-03-14 2003-09-18 Mcgill University Individualization of therapy with anxiolitics
EP1370865A2 (en) * 2001-03-14 2003-12-17 McGILL UNIVERSITY Metabolic phenotyping in therapy with immunosuppressants
WO2002095402A2 (en) * 2001-04-18 2002-11-28 Mcgill University Individualization of therapy with hyperlipidemia agents
US20030124636A1 (en) * 2001-04-18 2003-07-03 Mcgill University Individualization of therapy with antiarrhythmics
US20030103901A1 (en) * 2001-04-23 2003-06-05 Mcgill University ELISA kit for the determination of CYP2C19 metabolic phenotypes and uses thereof
WO2002086504A2 (en) * 2001-04-24 2002-10-31 Mcgill University Individualization of therapy with gastroesophageal reflux disease agents
CA2483758A1 (en) * 2001-04-30 2002-11-07 Mcgill University Individualization of therapy with antineoplastic agents
AU2002302223A1 (en) * 2001-05-07 2002-11-18 Mcgill University Individualization of therapy with analgesics
AU2002257451A1 (en) * 2001-05-17 2002-11-25 Mcgill University Individualization of therapy with antibiotic agents
US20030138375A1 (en) * 2001-06-06 2003-07-24 Mcgill University Individualization of therapy with Alzheimer's disease agents
WO2003008637A2 (en) * 2001-07-17 2003-01-30 Xanthus Life Sciences, Inc. Use of genotyping in the individualization of therapy
US20030195350A1 (en) * 2001-11-28 2003-10-16 Xanthus Life Sciences, Inc Individualization of therapy with antiviral agents
WO2003052123A1 (en) * 2001-12-19 2003-06-26 Xanthus Life Sciences, Inc. Individualization of therapy with antihistamines
WO2003052425A2 (en) * 2001-12-19 2003-06-26 Xanthus Life Sciences, Inc. Elisa kit for cyp 2c9 metabolic phenotypes
WO2003067257A1 (en) * 2002-02-08 2003-08-14 Mcgill University Individualization of therapy with anxiolitics
EP1497647A1 (en) * 2002-04-19 2005-01-19 Pfizer Products Inc. Test for measurement of therapeutic drug levels
WO2004003550A2 (en) * 2002-06-28 2004-01-08 Xanthus Life Sciences, Inc. Individualization of therapy with anticoagulants
US20040204862A1 (en) * 2003-04-11 2004-10-14 Wainer Irving W. Computer-based model for identification and characterization for non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors
WO2006039663A2 (en) 2004-09-30 2006-04-13 Vanda Pharmaceuticals, Inc Methods for the administration of iloperidone
CN102796102B (en) * 2012-06-13 2015-09-16 广州万孚生物技术股份有限公司 Caffeine haptens, conjugate and application, caffeine detection or measuring method
CN102925567B (en) * 2012-10-23 2013-12-11 山东省皮肤病性病防治研究所 Use of HLA-B*1301 alleles
CN111228518A (en) * 2020-02-19 2020-06-05 无锡艾德美特生物科技有限公司 Probe substrate for in vivo detection of CYP1A activity and application thereof
CN114605322B (en) * 2022-02-25 2023-06-27 华南农业大学 Dextromethorphan hapten, artificial antigen and antibody as well as preparation methods and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004757A1 (en) * 1993-08-06 1995-02-16 Board Of Regents, The University Of Texas System Use of monoclonal antibodies for determining sensitivity to acetylizable drugs
EP0645459A1 (en) * 1993-09-27 1995-03-29 Dorn C. Cook A method and apparatus for determining the role of cytochrome P450 and related enzymes in the metabolism of drugs and other chemicals
US5830672A (en) * 1996-01-31 1998-11-03 Wainer; Irving W. Elisa kit for the rapid determination of N-acetyltransferase (NAT2) phenotypes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004757A1 (en) * 1993-08-06 1995-02-16 Board Of Regents, The University Of Texas System Use of monoclonal antibodies for determining sensitivity to acetylizable drugs
EP0645459A1 (en) * 1993-09-27 1995-03-29 Dorn C. Cook A method and apparatus for determining the role of cytochrome P450 and related enzymes in the metabolism of drugs and other chemicals
US5830672A (en) * 1996-01-31 1998-11-03 Wainer; Irving W. Elisa kit for the rapid determination of N-acetyltransferase (NAT2) phenotypes

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BIOMARKERS, vol. 3, no. 3, May 1998 (1998-05-01), pages 205 - 218, ISSN: 1354-750X *
CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 47, no. 4, 1990, pages 470 - 477, ISSN: 0009-9236 *
CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 49, no. 6, 1991, pages 648 - 657, ISSN: 0009-9236 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1990, KILBANE A J ET AL: "HUMAN N-ACETYLATION GENOTYPE DETERMINATION WITH URINARY CAFFEINE METABOLITES", XP002144106, Database accession no. PREV199090015389 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1991, TANG B-K ET AL: "CAFFEINE AS A METABOLIC PROBE VALIDATION OF ITS USE FOR ACETYLATOR PHENOTYPING", XP002144105, Database accession no. PREV199192067910 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; May 1998 (1998-05-01), MEACHER DIANNE M ET AL: "Analysis of NAT and CYPIA2 phenotypes and NAT2* genotype by capillary electrophoresis.", XP002144107, Database accession no. PREV199800360878 *
WONG P ET AL: "Synthesis of caffeine metabolites derivatives for measuring CYP1A3 activity by ELISA.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 40, March 1999 (1999-03-01), 90th Annual Meeting of the American Association for Cancer Research;Philadelphia, Pennsylvania, USA; April 10-14, 1999, March, 1999, pages 53, XP002144104, ISSN: 0197-016X *

Also Published As

Publication number Publication date
EP1163518A2 (en) 2001-12-19
JP2002539450A (en) 2002-11-19
AU3138800A (en) 2000-10-04
CA2366085A1 (en) 2000-09-21
WO2000055624A2 (en) 2000-09-21

Similar Documents

Publication Publication Date Title
WO2000055624A3 (en) Elisa kit for the determination of metabolic phenotypes
Loomba et al. Heritability of hepatic fibrosis and steatosis based on a prospective twin study
ES2367311T3 (en) MAP-2 PROTEOLYTIC DEGRADATION PRODUCTS AS DIAGNOSTIC BIOMARCATORS FOR NEURAL INJURIES.
Kumar et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT
WO2006036220A3 (en) Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
Barouki et al. Integration of the human exposome with the human genome to advance medicine
Lai et al. The emerging role of the peptidome in biomarker discovery and degradome profiling
EP1842065A4 (en) Methods for diagnosis and prognosis of epithelial cancers
Junna et al. Serum AFU, 5’-NT and AFP as biomarkers for primary hepatocellular carcinoma diagnosis
Chen et al. Predicting the risk of sarcopenia in elderly patients with patellar fracture: development and assessment of a new predictive nomogram
Aldossari et al. Association between salivary amylase enzyme activity and obesity in Saudi Arabia
Birhan et al. Association of angiotensin-converting enzyme gene insertion/deletion polymorphisms with risk of hypertension among the Ethiopian population
Wu et al. Association between p21 codon 31 polymorphism and esophageal cancer risk in a Taiwanese population
Neugroschl et al. Biological markers in Alzheimer disease
WO2002017785A8 (en) Visceral adipose meter with body weighing function
Wang et al. Novel frame-shift mutations of GLI3 gene in non-syndromic postaxial polydactyly patients
Rutherford et al. HLA-DR2 predicts susceptibility and disease chronicity in Irish sarcoidosis patients.
WO2002086508A3 (en) Elisa kit for the determination of cyp2c19 metabolic phenotypes and uses thereof
Pannall et al. International federation of clinical chemistry: A strategy to promote the rational use of laboratory tests
Mullen Understanding Genotype–Phenotype Correlations in Patients with TBX4 Mutations: New Views Inside and Outside the Box
WO2003052425A3 (en) Elisa kit for cyp 2c9 metabolic phenotypes
Phanaksri et al. Plasma checkpoint protein 1 (Chk1) as a potential diagnostic biomarker for opisthorchiasis and cholangiocarcinoma
Salama et al. Plasma proteosome level as a potential marker for hepatocellular carcinoma
Zhou et al. Combined Serum Golgi Membrane Glycoprotein 73 Improves the Accuracy of Transient Elastography for Significant Fibrosis Detection in Patients with Chronic HBV Infections
Tan et al. Traditional and emerging cardiometabolic risk profiling among Asian youth with type 2 diabetes: a case-control study

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000908867

Country of ref document: EP

ENP Entry into the national phase

Ref country code: CA

Ref document number: 2366085

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 605205

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09936507

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000908867

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2366085

Country of ref document: CA

WWW Wipo information: withdrawn in national office

Ref document number: 2000908867

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载